Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
42
IDYA Quote, Financials, Valuation and Earnings
Last price:
$36.04
Seasonality move
:
2.99%
Day range:
$34.00 - $36.61
52-week range:
$13.45 - $36.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.83x
P/B ratio:
2.89x
Volume:
1.5M
Avg. volume:
970K
1-year change:
27.02%
Market cap:
$3.2B
Revenue:
$7M
EPS (TTM):
-$1.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$60M | -$0.55 | -15.05% | -37.84% | $49.47 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.21% | 32.99% | $130.63 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$130.5M | -$1.05 | -32.79% | -81.88% | $85.47 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $781.13 |
|
ZYME
Zymeworks, Inc.
|
$29.9M | -$0.32 | -34.51% | -8.4% | $34.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$36.01 | $49.47 | $3.2B | -- | $0.00 | 0% | 14.83x |
|
GILD
Gilead Sciences, Inc.
|
$122.62 | $130.63 | $152.1B | 18.99x | $0.79 | 2.56% | 5.30x |
|
GTBP
GT Biopharma, Inc.
|
$0.63 | $8.00 | $6.7M | -- | $0.00 | 0% | 59.35x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$81.81 | $85.47 | $13.3B | -- | $0.00 | 0% | 13.93x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$722.80 | $781.13 | $76B | 17.30x | $0.88 | 0.49% | 5.59x |
|
ZYME
Zymeworks, Inc.
|
$26.52 | $34.50 | $2B | -- | $0.00 | 0% | 14.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.755 | 1.14% | 12.20x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
ZYME
Zymeworks, Inc.
|
5.58% | 0.545 | 1.46% | 6.69x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
ZYME
Zymeworks, Inc.
|
$25M | -$22.1M | -17.82% | -18.82% | -80.07% | -$32.3M |
IDEAYA Biosciences, Inc. vs. Competitors
-
Which has Higher Returns IDYA or GILD?
Gilead Sciences, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of 39.21%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About IDYA or GILD?
IDEAYA Biosciences, Inc. has a consensus price target of $49.47, signalling upside risk potential of 37.38%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 6.54%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 GILDGilead Sciences, Inc.16 8 0 -
Is IDYA or GILD More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock IDYA or GILD?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.56% to investors and pays a quarterly dividend of $0.79 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or GILD?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. IDEAYA Biosciences, Inc.'s net income of $119.2M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.83x versus 5.30x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M GILDGilead Sciences, Inc.5.30x 18.99x $7.8B $3.1B
-
Which has Higher Returns IDYA or GTBP?
GT Biopharma, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About IDYA or GTBP?
IDEAYA Biosciences, Inc. has a consensus price target of $49.47, signalling upside risk potential of 37.38%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1170.25%. Given that GT Biopharma, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe GT Biopharma, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 GTBPGT Biopharma, Inc.1 0 0 -
Is IDYA or GTBP More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock IDYA or GTBP?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or GTBP?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than GT Biopharma, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than GT Biopharma, Inc.'s net income of -$3.1M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.83x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns IDYA or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -82.06%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About IDYA or IONS?
IDEAYA Biosciences, Inc. has a consensus price target of $49.47, signalling upside risk potential of 37.38%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.47%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 IONSIonis Pharmaceuticals, Inc.11 6 0 -
Is IDYA or IONS More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock IDYA or IONS?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or IONS?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.83x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M IONSIonis Pharmaceuticals, Inc.13.93x -- $156.7M -$128.6M
-
Which has Higher Returns IDYA or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of 38.89%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About IDYA or REGN?
IDEAYA Biosciences, Inc. has a consensus price target of $49.47, signalling upside risk potential of 37.38%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is IDYA or REGN More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock IDYA or REGN?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or REGN?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. IDEAYA Biosciences, Inc.'s net income of $119.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.83x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M REGNRegeneron Pharmaceuticals, Inc.5.59x 17.30x $3.8B $1.5B
-
Which has Higher Returns IDYA or ZYME?
Zymeworks, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -70.99%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Zymeworks, Inc.'s return on equity of -18.82%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B ZYMEZymeworks, Inc.90.64% -$0.26 $339M -
What do Analysts Say About IDYA or ZYME?
IDEAYA Biosciences, Inc. has a consensus price target of $49.47, signalling upside risk potential of 37.38%. On the other hand Zymeworks, Inc. has an analysts' consensus of $34.50 which suggests that it could grow by 30.09%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Zymeworks, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Zymeworks, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 ZYMEZymeworks, Inc.10 1 0 -
Is IDYA or ZYME More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.869%.
-
Which is a Better Dividend Stock IDYA or ZYME?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or ZYME?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Zymeworks, Inc. quarterly revenues of $27.6M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.83x versus 14.94x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M ZYMEZymeworks, Inc.14.94x -- $27.6M -$19.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
